Rx for Africa has announced the signing of letter of intent for a strategic alliance with Rusan Pharma of Mumbai, India. The alliance commences immediately, with Rusan providing Rx for Africa the tuberculosis (TB) drug, RUCOX-4 (four drug combination) as per the WHO recommended dosage. It is also approved by the Ethiopian Ministry of Health and already marketed in some CIS & African countries.
Mulugetta Bezzabeh, CEO, Rx for Africa, said: Tuberculosis is a huge problem in our region and RUCOX-4 is an important addition to our product line. We expect significant revenue and profit to be derived from marketing it.
Navin Saxena, Chairman, Rusan Pharma, Said: Rusan is pleased to enter into strategic alliance with Rx for Africa. Ethiopia is a big market with significant potential for growth in the area of Tuberculosis, HIV AIDS & Malaria products. Rusan has the capability to develop various drug delivery systems besides the conventional dosage forms and will use its expertise to bring these to the market in short time.